On October 9, Direxion Daily S&P Biotech Bull 3x Shares rose 8.25% in regular trading, trading at $239.0/share, with Turnover of $39.1446 million. The fund provides triple leveraged exposure to the S&P Biotechnology Select Industry Index, amplifying the index's rebound through leverage.

The move follows two consecutive sessions of sharp declines, with the ETF falling 8.24% on October 8 and 11.07% on October 7, as renewed rate-hike concerns pressured high-duration, zero-revenue biotech companies. Current price action indicates strengthening technical repair momentum after the oversold conditions, reflecting the amplified recovery in the biotech sector under leveraged effects.

The fund invests at least 80% of its net assets in financial instruments and securities of the index, ETFs that track the index, and other financial instruments that provide daily leveraged exposure to the index or ETFs that track the index. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards. The fund is non-diversified.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)